Clinical experience with orphan drugs for rare metabolic diseases.

Introduction: Inborn errors of metabolism are a highly heterogeneous group of orphan diseases. Diet therapy and enzyme and coenzyme replacement are the most frequently used treatment. There are few patients and published studies about inborn errors of metabolism.

[Clinical experience with orphan drugs for rare metabolic diseases].

Introduction: Inborn errors of metabolism are a highly heterogeneous group of orphan diseases. Diet therapy and enzyme and coenzyme replacement are the most frequently used treatment. There are few patients and published studies about inborn errors of metabolism.

Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.

Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.

Patients & Methods: The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry.

Results: We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment.

Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.

Background: Treatment based on nab-paclitaxel plus gemcitabine is one of the standard treatments for locally advanced or metastatic pancreatic adenocarcinoma. Not much information is available about its use in clinical practice. Looking for prognostic markers may aid in improving treatment plans for patients.

Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.

Aim: Obinutuzumab induces NK cell antibody-dependent cell-mediated cytotoxicity.

Objective: Investigate the effects on the human immune system after obinutuzumab monotherapy treatment in patients with chronic lymphocytic leukemia (CLL).

Method: To evaluate these effects, we analyzed the distribution of CD4 and CD8 T cells, B cells and NK cells in the peripheral blood of eight CLL patients who were treated with obinutuzumab in monotherapy.

Prevalence of the consumption of anticholinergic drugs in HIV patients.

Objective: To analyse anticholinergic agent consumption in HIV patients 50  years or older; to determine anticholinergic risk using the ACB and ARS scales;  and to determine if these patients use any type of benzodiazepine.

Method: A descriptive observational study of 256 HIV patients 50 years or  older.

Results: 73.